This article is more than 5 years old. Information may no longer be current.
VIDEO: Expert discusses FFR trial results at ACC 17
Click Here to Manage Email Alerts
WASHINGTON — In this Cardiology Today’s Intervention video perspective, B. Hadley Wilson, MD, FACC, discusses the results of three trials of pressure-wire fractional flow reserve presented at the American College Cardiology Scientific Session.
The COMPARE-ACUTE trial which suggested that patients with multivessel disease can be safely measured with FFR to determine if the nonculprit lesions should be treated.
“That trial did show that those patients benefited long-term who went and had [FFR] and then did have PCI if indicated,” Wilson, interventional cardiologist at Sanger Heart & Vascular Institute, Charlotte, North Carolina, said.
The IFR-SWEETHEART trial, according to Wilson, showed instantaneous wave-free ratio (iFR)-guided revascularization had similar outcomes to FFR-guided revascularization. In iFR’s favor, he said, is that it “can be [performed] without the use of adenosine and [results] can be obtained immediately.”
The DEFINE-FLARE trial, Wilson said, showed that iFR is as acceptable as traditional FFR for determining if blockages should be treated with PCI vs. medical therapy.